February 22nd, 2022
Harvard licenses kidney engineering technology to Trestle Biotherapeutics to facilitate new kidney replacement therapies
Powerful combination of 3D bioprinting and stem cell-based tissue engineering could enable new approaches to treating chronic kidney disease